1Colonna P,Iliceto S.Myocardial infarction and left ventricular remodeling:results of the CEDIM trial.Carnitine Ecocardiografia Digitalizzata Infarto Miocardico[J].Am Heart J,2000,139(2Pt3):124-129.
2Kaludercic N,Lindsey ML,Tavazzi B,et al.Inhibiting metallopruteases with PD 166793 in heart failure:pact on cardiac remodeling and beyond.Inhibiting metalloproteases with PD 166793 in heart failure:impact on cardiac remodeling and beyond[J].Cardiovaac Ther,2008 Spring,26(1):24-37.
3Galls ZS,Khatri JJ.Matrix metalloproteinases in vascular remodeling and atherogenesis:the good,the bad,and the ugly[J].Circulation Research,2002;90:251-262.
4Visse R,Naguse H.Matrix metallopruteinases and tissue inhibitors of metallopruteinases:structure,function,and biochemistry[J].Citc Res,2003,92(8):827-839.
5Ries C,Petrides PE.Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease[J].Biol Chem Hoppe Seyler,1995 Jun,376(6):345-355.
8Peterson JT,Li H,Dillon L,et al.Evolution of matrix metalloprotease and tissue inhibitor expression during heartfailure progression in the infracted rat[J].Cardiovasc Res,2000,46(2):307-315.
9Fedak PW,Altamentova SM,Weisel RD,et al.Matrix remodeling in experimental and human heart failure:a possible regulatory role for TIMP-3[J].Am JPbysiol,2003,284:626-634.
3Ducharme A,Frantz S,Aikawa M,et al.Targeted delection of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction[J].J Clin Invest,2000,106:55-62.
4Heymans S,luttun A,Nuyens D,et al.Inhibition of plasminogen activators or matrix metalloproteinase prevents cardiac rupture but impaires therapeutic angiogenesis and causes cardiac failure[J].Nat Med,1999,5:1135-1142.
5Spinale FG,Coker ML,Thomas CV,et al.Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure:relation to ventricular and myocyte function[J].Circ Res,1998,82(4):482-495.
6Rouet-Benzineb P,Gontero B,Dreyfus P,et al.Angiotensin Ⅱ induces nuclear factor-КB activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway[J].J Mol Cell Cardiol,2000,32:1767-1778.
7Guo H,Zucker S,Gordon MK,et al.Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cell[J].J Biol Chem,1997,272:24-27.
8Sato H,Kinoshita T,Takino T,et al.Activation of a recombinant membrane type-1 matrix metalloproteinase(MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases(TIMP-2)[J].Febs Lett,1996,393:101- 104.
9Li YY,Feng YQ,Kadokami T,et al.Myocardial extracellular matrix remodeling in transgenic mice overexpression tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy[J].Proc Natl Acad Sci USA,2000,97:12764-12751.
10Roten L,Nemoto S,Simsic J,et al.Effects of gene delection of the tissue inhibitor of the matrix metalloproteinase-type 1(TIMP-1) on left ventricular geometry and function in mice[J].J Mol Cell Cardiol,2000,32:109-120.
3Ocampo C, Ingram P, Ilbawi M, et al. Revisiting the surgical creation of volume load by aorto- caval shunt in rats [ J ]. Mol Cell Biochem,2003, 251(1 -2) :139 -143.
4Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post -infarc- tion heart : A review of cellular, molecular mechanisms, and therapeutic modalities [ J ]. Heart Fail Rev ,2011,16 ( 1 ) : 13 - 21.
5Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor[ J ]. Circulation ,2001,104 (7) :826 - 831.
6Lindsay M, Maxwell P, Dunn F. TIMP - 1 : A marker of left ventricular diastolic dysfunction and fibrosis in hypertension [ J ]. Hypertension, 2002,40(2) :136 - 141.
